TABLE OF CONTENTS
Volume 22, Issue 4 (April 2008)
Editorials
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy
P L Bergsagel
Leukemia 22: 673-675; doi:10.1038/leu.2008.2
C/EBP
, do not forget your TIP60
C W E So and B A van der Reijden
Leukemia 22: 676-677; doi:10.1038/leu.2008.16
Reviews
The role of CALM–AF10 gene fusion in acute leukemia
D Caudell and P D Aplan
Leukemia 22: 678-685; advance online publication, December 20, 2007; doi:10.1038/sj.leu.2405074
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L S Steelman, S L Abrams, J Whelan, F E Bertrand, D E Ludwig, J Bäsecke, M Libra, F Stivala, M Milella, A Tafuri, P Lunghi, A Bonati, A M Martelli and J A McCubrey
Leukemia 22: 686-707; advance online publication, March 13, 2008; doi:10.1038/leu.2008.26
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J A McCubrey, L S Steelman, S L Abrams, F E Bertrand, D E Ludwig, J Bäsecke, M Libra, F Stivala, M Milella, A Tafuri, P Lunghi, A Bonati and A M Martelli
Leukemia 22: 708-722; advance online publication, March 13, 2008; doi:10.1038/leu.2008.27
Original Articles
Acute Leukemias
E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia
C-h Zhong, V Prima, X Liang, C Frye, L McGavran, L Meltesen, Q Wei, T Boomer, M Varella-Garcia, J Gump and S P Hunger
Leukemia 22: 723-729; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405084
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
L Gu, N Zhu, H W Findley and M Zhou
Leukemia 22: 730-739; advance online publication, February 14, 2008; doi:10.1038/leu.2008.11
Chronic Myeloproliferative Disorders
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V Guerini, V Barbui, O Spinelli, A Salvi, C Dellacasa, A Carobbio, M Introna, T Barbui, J Golay and A Rambaldi
Leukemia 22: 740-747; advance online publication, December 13, 2007; doi:10.1038/sj.leu.2405049
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
H Konig, M Holtz, H Modi, P Manley, T L Holyoake, S J Forman and R Bhatia
Leukemia 22: 748-755; advance online publication, February 14, 2008; doi:10.1038/sj.leu.2405086
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A Tefferi, T L Lasho, J Huang, C Finke, R A Mesa, C Y Li, W Wu, C A Hanson and A Pardanani
Leukemia 22: 756-761; advance online publication, January 24, 2008; doi:10.1038/sj.leu.2405097
Cytogenetics and Molecular Genetics
Cooperative genetic defects in TLX3 rearranged pediatric T-ALL
P Van Vlierberghe, I Homminga, L Zuurbier, J Gladdines-Buijs, E R van Wering, M Horstmann, H B Beverloo, R Pieters and J P P Meijerink
Leukemia 22: 762-770; advance online publication, January 10, 2008; doi:10.1038/sj.leu.2405082
Minimal Residual Disease
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
T Flohr, A Schrauder, G Cazzaniga, R Panzer-Grümayer, V van der Velden, S Fischer, M Stanulla, G Basso, F K Niggli, B W Schäfer, R Sutton, R Koehler, M Zimmermann, M G Valsecchi, H Gadner, G Masera, M Schrappe, J J M van Dongen, A Biondi and C R Bartram
Leukemia 22: 771-782; advance online publication, January 31, 2008; doi:10.1038/leu.2008.5
Immunology
High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease
A Sergeeva, Y Ono, R Rios and J J Molldrem
Leukemia 22: 783-790; advance online publication, January 24, 2008; doi:10.1038/sj.leu.2405104
Sensitivity and Resistance to Therapy
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism
J Liu, S Joha, T Idziorek, S Corm, D Hetuin, N Philippe, C Preudhomme and B Quesnel
Leukemia 22: 791-799; advance online publication, January 24, 2008; doi:10.1038/leu.2008.3
Oncogenes, Fusion Genes and Tumor Suppressor Genes
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBP
D Bararia, A K Trivedi, A A Peer Zada, P A Greif, M A Mulaw, M Christopeit, W Hiddemann, S K Bohlander and G Behre
Leukemia 22: 800-807; advance online publication, January 31, 2008; doi:10.1038/sj.leu.2405101
Apoptosis
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
W Zhang, M Konopleva, V R Ruvolo, T McQueen, R L Evans, W G Bornmann, J McCubrey, J Cortes and M Andreeff
Leukemia 22: 808-818; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405098
Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells
S Inoue, R Walewska, M J S Dyer and G M Cohen
Leukemia 22: 819-825; advance online publication, January 31, 2008; doi:10.1038/leu.2008.1
Lymphoma
KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells
L Haddad, H El Hajj, R Abou-Merhi, Y Kfoury, R Mahieux, M El-Sabban and A Bazarbachi
Leukemia 22: 826-834; advance online publication, December 20, 2007; doi:10.1038/sj.leu.2405081
Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype
A Ehlers, E Oker, S Bentink, D Lenze, H Stein and M Hummel
Leukemia 22: 835-841; advance online publication, February 7, 2008; doi:10.1038/leu.2008.12
Myeloma
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J F San-Miguel, P G Richardson, P Sonneveld, M W Schuster, D Irwin, E A Stadtmauer, T Facon, J-L Harousseau, D Ben-Yehuda, S Lonial, H Goldschmidt, D Reece, J Bladé, M Boccadoro, J D Cavenagh, R Neuwirth, A L Boral, D-L Esseltine and K C Anderson
Leukemia 22: 842-849; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405087
Suppression of abnormal karyotype predicts superior survival in multiple myeloma
V Arzoumanian, A Hoering, J Sawyer, F van Rhee, C Bailey, J Gurley, J D Shaughnessy Jr, E Anaissie, J Crowley and B Barlogie
Leukemia 22: 850-855; advance online publication, January 17, 2008; doi:10.1038/sj.leu.2405091
Letters to the Editor
A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment
S Schnittger, U Bacher, W Kern, T Haferlach, B Hertenstein and C Haferlach
Leukemia 22: 856-858; advance online publication, September 13, 2007; doi:10.1038/sj.leu.2404949
Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study
A Zangrando, F Intini, G te Kronnie and G Basso
Leukemia 22: 858-861; advance online publication, September 13, 2007; doi:10.1038/sj.leu.2404952
Clonal expansion of non-leukemic cells expressing two novel MLL–ELL variants differing in transforming activity
M Takeuchi, C Nakaseko, S Miyagi, Y Takeda, S Ozawa, C Ohwada, R Cho, M Nishimura, Y Saito and A Iwama
Leukemia 22: 861-864; advance online publication, September 20, 2007; doi:10.1038/sj.leu.2404954
Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al.
D Westerman and S Juneja
Leukemia 22: 864-865; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404963
Reply to 'Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al.' by Westerman et al.
A Alvarez-Larrán, F Cervantes and C Besses
Leukemia 22: 865-866; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404964
Reply to 'Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán et al. Leukemia 2007; 21: 1218–1223'
D Westerman and S Juneja
Leukemia 22: 866; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404966
Reply to Westerman et al.: 'Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al. Leukemia 2007; 21: 1218–1223'
A Alvarez-Larrán, F Cervantes and C Besses
Leukemia 22: 866-867; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404967
Erythroid variant of chronic myelogenous leukemia
N Talreja, H Abdulhaq, R K Shadduck, J Rossetti, A Jalil, A Makary and J Lister
Leukemia 22: 867-870; advance online publication, November 22, 2007; doi:10.1038/sj.leu.2404965
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
C M Butcher, U Hahn, L B To, J Gecz, E J Wilkins, H S Scott, P G Bardy and R J D'Andrea
Leukemia 22: 870-873; advance online publication, October 4, 2007; doi:10.1038/sj.leu.2404971
Contribution of GM-CSF and IL-8 to the CD44-induced differentiation of acute monoblastic leukemia
J Delaunay, N Lecomte, S Bourcier, J Qi, Z Gadhoum, L Durand, C Chomienne, J Robert-Lézénès and F Smadja-Joffe
Leukemia 22: 873-876; advance online publication, October 4, 2007; doi:10.1038/sj.leu.2404976
Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia
A Quintás-Cardama, D L Gibbons, J Cortes, D Bobadilla, M L Slovak, H Kantarjian and L V Abruzzo
Leukemia 22: 877-878; advance online publication, October 11, 2007; doi:10.1038/sj.leu.2404981
Effect of parental history of cancer on the development of second neoplasms after lymphoma at the same site than the parents
J Lorenzo Bermejo, J Sundquist and K Hemminki
Leukemia 22: 879-880; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404982
The genetic characterization of acute promyelocytic leukemia with cryptic t(15;17) including a new recurrent additional cytogenetic abnormality i(17)(q10)
M Kim, J Lim, Y Kim, K Han, D H Lee, N G Chung, B Cho, H K Kim, K S Eom, C-K Min and W-S Min
Leukemia 22: 881-883; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404989
Proteasome inhibition therapies in childhood cancer
F Zaman, B Fadeel and L Sävendahl
Leukemia 22: 883-884; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2404997
Reply to 'Proteasome inhibition therapies in childhood cancer' by Zaman et al.
E Terpos and O Sezer
Leukemia 22: 884-885; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2404998
Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1 T315I and other mutants compared to direct sequencing of the ABL1 kinase domain
A Quintás-Cardama, D L Gibbons, H Kantarjian, M Talpaz, N Donato and J Cortes
Leukemia 22: 885-888; advance online publication, February 28, 2008; doi:10.1038/leu.2008.42
Corrigendum
Expression and mutation status of candidate kinases in multiple myeloma FREE
J O Claudio, F Zhan, L Zhuang, R Khaja, Y X Zhu, K Sivananthan, S Trudel, E Masih-Khan, R Fonseca, P L Bergsagel, S W Scherer, J Shaughnessy and A K Stewart
Leukemia 22: 889-890; doi:10.1038/sj.leu.2405095
